Compare Stocks → Strange new buyer driving up gold (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBAYNASDAQ:EOLSNASDAQ:FLXNNASDAQ:NEPTNASDAQ:OBSV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBAYCymaBay Therapeutics$32.48$32.24$7.26▼$32.50$3.73B0.324.11 million shs73 shsEOLSEvolus$11.53-0.3%$13.64$7.07▼$15.43$668.05M1.45625,641 shs348,448 shsFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/ANEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsOBSVObsEva$0.01$0.03$0.08▼$2.14$390K0.688.94 million shs11,112 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBAYCymaBay Therapeutics0.00%0.00%0.00%+32.57%+224.15%EOLSEvolus-0.69%-8.90%-17.31%-2.45%+38.28%FLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%NEPTNeptune Wellness Solutions0.00%0.00%0.00%-59.18%-99.22%OBSVObsEva0.00%0.00%-66.67%-85.71%-94.29%Strange new buyer driving up gold (Ad)One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBAYCymaBay Therapeutics0.9025 of 5 stars2.00.00.04.70.02.50.6EOLSEvolus4.1827 of 5 stars3.53.00.03.53.22.50.6FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideEOLSEvolus3.00Buy$20.6078.66% UpsideFLXNFlexion TherapeuticsN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/ACurrent Analyst RatingsLatest OBSV, NEPT, CBAY, EOLS, and FLXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/1/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.002/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/13/2024CBAYCymaBay TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/13/2024CBAYCymaBay TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$32.502/13/2024CBAYCymaBay TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$29.00 ➝ $32.50(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59EOLSEvolus$202.09M3.31N/AN/A($0.36) per share-32.03FLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00OBSVObsEva$20.11M0.02N/AN/A$0.41 per share0.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)EOLSEvolus-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/14/2024 (Estimated)FLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%7/15/2024 (Estimated)OBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/ALatest OBSV, NEPT, CBAY, EOLS, and FLXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 million2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBAYCymaBay TherapeuticsN/A10.9610.96EOLSEvolusN/A2.332.10FLXNFlexion TherapeuticsN/A4.384.05NEPTNeptune Wellness SolutionsN/A0.230.10OBSVObsEvaN/A0.610.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBAYCymaBay Therapeutics95.03%EOLSEvolus90.69%FLXNFlexion Therapeutics90.01%NEPTNeptune Wellness Solutions14.44%OBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipCBAYCymaBay Therapeutics7.00%EOLSEvolus5.40%FLXNFlexion Therapeutics9.13%NEPTNeptune Wellness Solutions5.10%OBSVObsEva14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableEOLSEvolus27357.94 million54.82 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableOBSV, NEPT, CBAY, EOLS, and FLXN HeadlinesSourceHeadlineObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 12 at 2:16 AMObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listinglobenewswire.com - April 3 at 1:00 AMObsEva Announces Update on Board of Directorsglobenewswire.com - March 19 at 2:00 AMObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023globenewswire.com - February 28 at 1:00 AMObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Datesbenzinga.com - February 26 at 12:34 AMObsEva SA OBSNmorningstar.com - November 11 at 10:37 PMObsEva SA OBSEFmorningstar.com - November 11 at 7:36 AMObsEva (NASDAQ: OBSV)fool.com - June 18 at 11:34 PMTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObservernews.google.com - May 10 at 1:37 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Financenews.google.com - May 2 at 1:32 PMObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaqnews.google.com - May 2 at 8:31 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswirenews.google.com - May 2 at 1:20 AMGameto Appoints Teri Loxam as Chief Financial Officer - citybiznews.google.com - April 28 at 11:20 PMObsEva Annual Report 2022 - Marketscreener.comnews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Yahoo Financenews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Benzinganews.google.com - April 28 at 1:20 PMObsEva Annual Report 2022 - EIN Newsnews.google.com - April 28 at 1:20 PMGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswirenews.google.com - April 28 at 8:19 AMEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journalnews.google.com - April 26 at 6:27 PMEndometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPRnews.google.com - April 23 at 8:45 PMObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.comnews.google.com - April 21 at 3:44 PMObsEva Announces Change of Central Securities Depositary - Yahoo Financenews.google.com - April 20 at 11:41 PMObsEva Announces Change of Central Securities Depositary - GlobeNewswirenews.google.com - April 20 at 1:10 AMTackling Reproductive Health and Fertility Care - Pharmaceutical Executivenews.google.com - April 13 at 6:41 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Flexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.Neptune Wellness SolutionsNASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.